Long-Term Efficacy of Guselkumab on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through Two Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Biologic-Naïve Patients With Psoriatic Arthritis
September 2023
in “
Journal of the American Academy of Dermatology
”
Studysummary Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer